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Introduction
Wound healing is a dynamic, interactive process consisting of
three major phases that overlap in time: inflammation, granulation
tissue development (including re-epithelialisation) and tissue
remodelling [1]. Granulation tissue development involves the gen-
eration of new connective tissue and new blood vessels within the
wound during the healing process. Angiogenesis, the process of
generation of new blood vessels from pre-existing vessels, func-
tions to provide oxygen and nutrients to the injured area and is a
key step in the development of the healing (granulation) tissue.
The proper development of this tissue establishes the foundation
for the subsequent events during the healing process, including
wound contraction and generation of wound tensile strength.
Angiogenesis is necessary for normal wound healing. Indeed,
when angiogenesis is decreased, the result is impaired healing [2].
The development of new blood vessels requires the proliferation and
migration of endothelial cells [3], which is initiated by a cross-talk
between cells and the surrounding microenvironment. This includes
signals stimulated by numerous factors, such as acidic and basic
FGF, VEGF, TGF- and angiogenin [4, 5]. The work presented here
shows that insulin is another stimulator of angiogenesis.
The use of insulin for non-diabetic purposes began in the early
part of the twentieth century [6, 7] and has been used to improve
bone healing in rats [8], incision or burn wounds of the skin [9, 10]
and cutaneous ulcerations in diabetic and non-diabetic mice [11].
Insulin also appears to exert some effects on the vasculature.
Previous studies have shown that insulin has vasculo-protective
effects on endothelial cells by stimulating the release of NO from
these cells [12, 13]. NO is a potent modulator of microvascular
 permeability [14]; it inhibits oxidant-induced dysfunction of the
endothelial cell barrier [15] and reduces reperfusion-induced
 cardiac injury [16]. Furthermore, it has been shown in an experi-
mental mouse model system for retinopathy developed during pre-
mature birth that mice lacking expression of the insulin receptor in
vascular endothelial cells exhibit reduced retinal neovascularisation
when compared with controls. A similar, though weaker, effect was
seen in mice lacking insulin-like growth factor (IGF) receptor in
endothelial cells [17], suggesting the important role of insulin and,
to a lesser extent, of IGF in angiogenesis. However, little is known
about the mechanisms by which insulin stimulates angiogenesis.
The question still remains: Is insulin an angiogenic molecule?
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Abstract
Angiogenesis, the development of new blood vessel from pre-existing vessels, is a key process in the formation of the granulation tis-
sue during wound healing. The appropriate development of new blood vessels, along with their subsequent maturation and differentia-
tion, establishes the foundation for functional wound neovasculature. We performed studies in vivo and used a variety of cellular and
molecular approaches in vitro to show that insulin stimulates angiogenesis and to elucidate the signalling mechanisms by which this
protein stimulates microvessel development. Mice skin injected with insulin shows longer vessels with more branches, along with
increased numbers of associated -smooth muscle actin-expressing cells, suggesting the appropriate differentiation and maturation of
the new vessels. We also found that insulin stimulates human microvascular endothelial cell migration and tube formation, and that
these effects occur independently of VEGF/VEGFR signalling, but are dependent upon the insulin receptor itself. Downstream signalling
pathways involve PI3K, Akt, sterol regulatory element-binding protein 1 (SREBP-1) and Rac1; inhibition of these pathways results in
elimination of endothelial cell migration and tube formation and significantly decreases the development of microvessels. Our findings
strongly suggest that insulin is a good candidate for the treatment of ischaemic wounds and other conditions in which blood vessel
development is impaired.
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To determine whether insulin is angiogenic in vivo, we per-
formed subcutaneous injections of this protein in the dermis of
mice, and to determine the mechanism of action, we used human
microvascular endothelial cells (HMEC) in culture. Our results
show for the first time that insulin stimulates the development of
new microvessels, and that these microvessels are associated with
-smooth muscle actin (-SMA)-expressing cells and that they are
more branched than those in vehicle-injected animals. The studies
in culture suggest that this occurs by stimulation of endothelial cell
migration and tube formation through a PI3K-Akt-sterol regulatory
element-binding protein-1 (SREBP-1) signalling pathway that leads
to the activation of Rac1. Our findings strongly suggest that insulin
is a useful tool for the improvement of wounds impaired in vascu-
larisation and also for situations in which ischaemia is present.
Materials and Methods
Reagents
A human microvascular endothelial cell line, HMEC-1, was a gift from 
the Center for Disease Control (Atlanta, GA, USA). Plasmids expressing the
constitutively active form of Rac1 (V12, Rac1-CA), the dominant-negative
mutant of Rac1 (N17, Rac1-DN) and the wild-type Rac1 (Rac1-WT) 
were the gifts from Miguel Del Pozo (Centro National de Investigaciones
Cardiovasculares, Madrid, Spain). DMEM was purchased from Mediatech
(Manassas, VA, USA) and FBS from Atlanta Biologicals (Lawrenceville, GA,
USA). Anti-SREBP-1(2A4), anti-Akt, anti-RhoA (sc-179) and anti-VEGF (A-20)
antibodies (Ab) were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Anti-phospho-Akt Ser (473) and anti-insulin receptor
(29B4) Ab as well as the PI3K inhibitor LY294002 were purchased from
Cell Signaling (Danvers, MA, USA). The TRITC-antimouse Rac1 and rat
antimouse CD31 Ab (PECAM-1, IHC) were purchased from Becton
Dickinson and Company (Franklin Lakes, NJ, USA). Anti-GAPDH Ab was
obtained from RDI Research Diagnostics (Concord, MA, USA). The IGF-1
receptor inhibitor picropodophyllin and the VEGFR2 inhibitor SU1498
came from EMD Biosciences (San Diego, CA, USA). Recombinant human
insulin, 25-hydroxycholesterol (25-HC) and anti--SMA Ab were pur-
chased from Sigma (St. Louis, MO, USA). FITC-conjugated goat antimouse
immunoglobulin came from Dako (DK, Glostrup, Denmark), antimouse
Texas Red Ab from Amersham, and FITC-conjugated goat antirat
immunoglobulin from Zymed Laboratories, Inc. (South Francisco, CA,
USA). Humulin Ultralene human insulin (rDNA origin) extended zinc sus-
pension was purchased from Eli Lilly and Company (Indianapolis, IN,
USA). Human VEGF was purchased from Peprotech (Rocky Hill, NJ, USA),
and Lipofectin® transfection reagent was purchased from Invitrogen
(Carlsbad, CA, USA). The Rac activation assay kit came from Cell Biolabs,
Inc. (San Diego, CA, USA).
In vivo angiogenesis model
C57BL/6J mice were purchased from The Jackson Laboratory (USA) and
housed at the University of California, Riverside (UCR) vivarium. All exper-
imental protocols were approved by the UCR Institutional Animal Care and
Use Committee. Experiments were performed with 8- to 12-week-old mice.
Mice were anesthetized with a single intraperitoneal injection of ketamine
(80 mg/kg body weight)/xylazine (16 mg/kg body weight). One day prior to
treatment, the hair was removed from the back of the mice using the Nair
hair remover (Madera, CA, USA). Insulin (0.03 U/20 l saline) or saline 
(20 l) were injected at symmetric sites on the back using an insulin
syringe every 24 hrs for 5 days, and skin samples from the injected areas
were collected at day 6. Experiments involving the use of 25-HC were
 performed by injecting each mouse at four sites on the back with insulin
(0.03 U/20 l saline), saline (20 l), 25-HC (0.5 mg/ml, 20 l) or 25-HC
(1 mg/ml, 10 l)  insulin (0.03 U/10 l saline). The injection sites were
rotated clockwise in different mice in order to compensate for the varia-
tions from different anatomic distribution. At the sites in which 25-HC was
used, this inhibitor was pre-injected 24 hrs before the first insulin treat-
ment at the assigned injection site, then with insulin every 24 hrs for 
5 days. In all cases, the injection sites were labelled using a permanent
marker pen to ensure that all injections for the same site were located in
the same place, and that the two injection sites on the same animal were
not less than 2 cm apart to avoid possible cross-over effects. Skin samples
were collected at day 6 after initiation of insulin treatment.
Preparation of tissues for histology
The animals were anesthetized, as described above, and skin samples were
collected using a skin punch biopsy (7 mm in diameter) (Acuderm, Inc.).
The tissues were fixed in 4% paraformaldehyde, incubated with 0.1 M
glycine/PBS for 1 hr, then incubated with 15% and 30% sucrose before
embedding in OCT (Tissue-Tek; Sakura Finetek, Inc., USA) and then frozen
and stored at –80C. For CD31 staining samples, the tissues were embed-
ded directly in OCT and were frozen. After sample collection, the mice were
killed using CO2.
Cell culture
HMEC-1 cells were cultured in 5% CO2 at 37C in DMEM supplemented
with 10% FBS, 10 units/ml penicillin and 10 g/ml streptomycin sulphate
(GIBCO; Invitrogen Corp.).
Cell proliferation assay
DNA synthesis was assessed by BrdU incorporation using a BrdU prolifer-
ation assay kit (EMD Biosciences). Cells seeded in the 96-well tissue cul-
ture plates (1  104 cells/well) were subjected to treatment with different
concentrations of insulin for 24 or 48 hrs in the presence of BrdU. After fix-
ation, the cells were processed according to the manufacturer’s protocol.
Briefly, 100 l anti-BrdU Ab was added to each well and incubated for 1 hr.
After washing, 100 l/well peroxidase goat antimouse IgG HRP was added
to the cells, followed by incubation for 30 min. and addition of 100 l of
substrate solution for 15 min. and then the reaction was stopped by adding
100 l of stop solution. The relative incorporation of BrdU was determined
by reading the absorbance at 450 nm using a spectrometer.
In vitro cell migration assay
The cloning ring assay was used to monitor cell migration. In total, 2.0 
104 cells were plated in a cloning ring with a 6-mm-diameter set within a
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35-mm culture dish. Two hours after seeding, the cylinder was removed,
the cell edges were marked and migration was measured at the indicated
time-points by quantification of the distance from the initial cell edge to the
edge of the migrating cells.
Endothelial cell tube formation assay
Twenty microlitres of Matrigel (Becton Dickinson) were applied to the cen-
tre of the 35-mm cell culture dishes to evenly coat an area with a diameter
of 1.5 cm. The coated plates were incubated for 1 hr at room temperature.
The endothelial cells, with or without transfection of different mutants of
Rac1, were plated on the Matrigel-coated area at a density of 1.5  104
cells, then treated as indicated above and incubated for 20 hrs. Tube for-
mation was observed with an inverted phase contrast microscope (Nikon,
Tokyo, Japan).
Immunoblotting
The cells were treated as indicated above, washed with ice-cold 1 PBS
and lysed on ice with a lysis buffer containing 10 mM Tris, 0.5% Triton 
X-100, 0.5% Nonidet P-40, pH 7.5, 2.5 mM KCl, 150 mM NaCl, 30 mM 
-glycerophosphate, 50 mM NaF, 1 mM Na3VO4 and 0.1% SDS and with
additional protease and phosphatase inhibitor cocktails (Sigma). Protein
concentrations were measured using the DC protein assay kit (Bio-Rad).
Equal protein concentrations of the cell extracts were mixed with the sam-
ple buffer, boiled and analysed using 10% acrylamide SDS-PAGE.
Immunoblotting was performed with the indicated primary Ab and the
appropriate HRP-conjugated secondary Ab, followed by incubation with
West Dura extended duration substrate (Pierce Biotechnology). Blots were
then re-probed for housekeeping proteins to ensure equal loading.
Rac1 pull-down assay
The cells were treated as indicated above, washed with ice-cold 1 PBS,
and lysed on ice with 1 lysis buffer and the cell lysates collected and
cleared by centrifugation. Thirty microlitres of cell lysates were mixed with
the sample buffer for loading control. The remainder of the cell lysates
were then mixed with PAK PBD agarose bead slurry and incubated at 4C
for 1 hr with gentle agitation. The beads were pelleted by centrifugation and
washed three times with 0.5 ml of 1 assay buffer. The bead pellets were
resuspended in 40 l of 2 reducing SDS-PAGE sample buffer and boiled
for 5 min. The pull-down supernatant was then analysed by SDS-PAGE and
immunoblotting with an anti-Rac1 Ab.
Transient transfections
Plasmids expressing Rac1-CA, Rac1-DN and Rac1-WT were transfected
using Lipofectin (Invitrogen, USA), according to the manufacturer’s proto-
col. Briefly, one day before transfection, the cells were plated in a growth
medium without antibiotics. Transfections were performed at 40–60% cell
confluency. DNA (2 g) in 100 l of DMEM without serum was mixed gen-
tly with 5 l Lipofectin in 100 l of DMEM without serum. This mixture
was incubated for 15 min. at room temperature and added to the cells,
which were then incubated at 37C and 5% CO2 for 5 hrs. At this time, the
medium was replaced with a serum-containing medium.
Immunolabelling
The cells were cultured in chamber slides (Nunc), fixed in 4% paraformalde-
hyde for 30 min., rinsed with PBS, incubated in 0.1 M glycine/PBS for 
20 min. and blocked with 3% BSA, 0.1% Triton X-100/PBS for 30 min.
Primary Ab in 1% BSA/PBS were applied to the sample for 2 hrs at room
temperature, washed and incubated with Texas Red or FITC-conjugated sec-
ondary Ab for 1 hr at room temperature. After washing, the cells were
mounted in Vectashield-containing DAPI (Vector Laboratories, Inc.).
Immunolabelling was visualised and imaged using a Leica SP2 laser scan-
ning confocal microscope (Allendale, NJ, USA). For frozen tissues, 8-m
cryosections were washed to remove the OCT, fixed in 2% paraformalde-
hyde for 30 min. and incubated in 0.1 M glycine/PBS for 20 min., followed
by the primary and secondary Ab using the same procedure as indicated
above. For CD31 staining samples, cryosections were fixed by incubation
with ice-cold acetone for 30 min. and incubated in 0.1 M glycine/PBS for 
20 min.; the remainder of the procedure was identical to that indicated above.
Statistical analysis
Data are shown as mean  standard deviation (SD). Data analysis was per-
formed using the unpaired Student’s t-test on raw data with GraphPad
Instat software (GraphPad Software, Inc.).
Results
Subcutaneous injections of insulin stimulate
angiogenesis in vivo.
Insulin stimulates wound healing in mouse excision wounds and
rat burn wounds [10]. Angiogenesis is a critical and necessary step
for wound healing. Therefore, we hypothesize that insulin affects
angiogenesis during wound healing, and that this is one of the
ways by which it stimulates improvement of the healing process.
To test this possibility, we injected 0.03 units of insulin subcuta-
neously in the mouse dorsum every 24 hrs. After 5 days of insulin
treatment, samples were collected from the injected area, and the
extent of angiogenesis was determined by quantification of CD31
staining, a marker of endothelial cells, to determine the overall
blood vessel area. Insulin increases the area occupied by the CD31-
positive cells (Fig. 1 A–C) and stimulates the development of longer
vessels with more branches (Fig. 1A and B). We also determined
the numbers of blood vessels expressing -SMA, a marker of per-
icytes and smooth muscle cells, that are associated with vessels
which have undergone maturation and differentiation and found
that insulin stimulates a significant increase in the number of 
-SMA-expressing cells associated with blood vessels (Fig. 1D).
Insulin stimulates microvascular endothelial cell
migration in a time- and dose-dependent manner
We used HMEC to determine the effects of insulin on endothelial
proliferation and migration, processes involved in angiogenesis.
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BrdU incorporation assays were performed to detect DNA 
synthesis, and thus proliferation, in endothelial cells after treat-
ment with multiple concentrations of insulin. Concentrations
ranging from 10	8 M to 10	5 M insulin did not significantly
change BrdU incorporation, showing that insulin does not stim-
ulate endothelial cell proliferation (Fig. 2A). Cell migration was
measured using the cloning ring migration assay. In this assay,
the cells were treated with different concentrations of insulin to
identify potential effects of insulin on migration and examine
dose-dependent effects. A concentration of 10	8 M insulin
slightly increased endothelial cell migration after 48 hrs of treat-
ment. Concentrations ranging from 10	7 M to 10	5 M insulin
significantly enhanced endothelial cell migration after 24 hrs of
treatment (Fig. 2 B and C).
Insulin stimulates microvascular endothelial cell
migration via the insulin receptor
Insulin and IGF-1 receptors are tyrosine kinase receptors that
share 60% homology. Insulin and IGF-1 bind, and activate, both
receptors, although they bind the receptors with different affinities
[18]. To determine which receptors mediate the effect of insulin on
endothelial cell migration, we pre-treated the microvascular
endothelial cells with either the neutralizing insulin receptor Ab, Ab
29B4, or the IGF-1 receptor tyrosine kinase inhibitor, picrop-
odophyllin, and then treated the cells with 10	7 M or 10	6 M
insulin. Pre-treatment with the insulin receptor Ab completely
abolished 10	7 M insulin-induced migration but only partially
blocked 10	6 M insulin-induced migration (Fig. 3A). We also
found that picropodophyllin did not affect 10	7 M insulin-induced
migration but did inhibit 10	6 M insulin-induced migration (Fig. 3B).
These results suggest that the effects of higher concentrations
(10	6 M) of insulin on endothelial cell migration are mediated by
both the insulin and the IGF-1 receptors, whereas the effects of
lower concentrations of insulin (10	7 M) are primarily mediated
by the insulin receptor. To study the effects of insulin that are
mediated only through the insulin receptor and its associated
downstream signalling pathways, 10	7 M insulin was chosen for
the subsequent studies, except when otherwise indicated.
Insulin is known to stimulate VEGF secretion in various cell types,
and this growth factor is known to stimulate endothelial cell migra-
tion and angiogenesis [3, 19, 20]. Indeed, following 24 and 48 hrs of
insulin treatment, we detected elevated VEGF levels in the endothe-
lial cell culture medium (Fig. 3C). In order to determine whether
insulin-induced endothelial cell migration is mediated by VEGF, we
pre-treated the cells with SU1498, a selective inhibitor of the VEGF
receptor 2 (VEGFR-2), prior to treatment with insulin or VEGF and
measured migration distances at 24 and 48 hrs. This VEGFR inhibitor
completely abolished VEGF-induced cell migration but did not alter
insulin-induced migration (Fig. 3D), suggesting that insulin-induced
endothelial cell migration does not require VEGFR signalling.
PI3K and Akt mediate insulin-induced 
microvascular endothelial cell migration 
and tube formation
The activation of PI3K-Akt is important for growth factor-induced
cell proliferation, migration and survival. Therefore, we investigated
Fig. 1 Subcutaneous injection of insulin stimulates angiogenesis in mouse
skin: C57BL/6J mice (n 
 6) were injected with insulin (0.03 U/20 l
saline) or saline (20 l) subcutaneously at symmetric sites on the dorsum
every 24 hrs for 5 days, and skin samples from the injected areas were col-
lected at day 6. Tissue slides were stained with either anti-CD31 (PECAM-1)
or anti--SMA, followed by FITC-conjugated goat antirat or goat anti-
mouse secondary antibodies. Staining was visualised and pictures were
taken using a Nikon immunofluorescence microscope (Bethesda, ML,
USA). (A, B) Representative immunofluorescence images of CD31 stain-
ing: (A) control, (B) insulin; magnification 40. Insulin injection results in
the formation of longer blood vessels with more branches. (C) Percentage
of CD31-positive cell area: the fraction of CD31-positive cell area relative
to the total tissue area of each high-power field was measured using
ImageJ software. At least eight fields per group were analysed. Insulin
increases the percentage of the CD31-positive cell area. Data are shown as
the mean value  SD. Statistics indicate differences between the treat-
ment and control. ***P  0.001 versus control. (D) The number of blood
vessels that express -SMA were counted using fluorescence microscopy,
and the vessel number was normalised by dividing by the total tissue
 section area. Insulin increased the number of -SMA-positive blood
 vessels. Data are shown as the mean value  SD. Statistics indicate
 differences between the treatment and control.*P  0.05 versus control.
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whether insulin promotes the phosphorylation/activation of Akt
and found that the levels of phosphorylated Akt increased after 3
min. of insulin treatment and remained elevated for at least 60
min. (Fig. 4A). This effect was dose-dependent, with the higher
insulin concentrations stimulating stronger Akt phosphorylation
(Fig. 4B). Akt is phosphorylated and activated downstream of PI3K
[21]; indeed, inhibition of PI3K with LY294002 prevented insulin-
induced Akt phosphorylation (Fig. 4C). We also used this inhibitor
to determine the importance of PI3K-Akt activity in insulin-
induced cell migration and tube formation and found that inhibi-
tion of the PI3K-Akt pathway abolished both insulin-mediated
processes (Fig. 4D and E). These results show that insulin stimu-
lation of endothelial cell migration and tube formation is depend-
ent upon PI3K and Akt.
SREBP-1 is involved in insulin-induced 
microvascular endothelial cell migration 
and angiogenesis
SREBPs are key transcription factors that regulate cholesterol and
fatty acid biosynthesis pathways and are thus important in mem-
brane lipid biosynthesis [22]. Because of the relationship between
the microviscosity of the cell membrane and cell motility, it is pos-
sible that SREBP activation is important in the effects of insulin on
endothelial cell migration. Therefore, we investigated whether
insulin treatment promotes SREBP-1 activation in endothelial cells,
and whether this activation is involved in insulin-induced cell migra-
tion. Immunoblot analysis using Ab that recognise specifically the
Fig. 2 Insulin stimulates microvascular endothelial cell migration, but not proliferation, in a time- and dose-dependent manner. (A) HMEC-1 cells seeded
in the 96-well tissue culture plates (1.0  104 cells/well) were subjected to treatment with different concentrations of insulin for 24 or 48 hrs in the
presence of BrdU. After fixation, the cells were processed according to the protocol of the manufacturer. Data are shown as the mean value  SD. There
were no statistically significant differences in endothelial cell proliferation following insulin treatment. (B, C) Cells were plated within cloning rings, the
edges were marked and then the cells were treated with 10	8 M, 10	7 M, 10	6 M or 10	5 M insulin, respectively. Migration distance was measured at
24 and 48 hrs after treatment. Each treatment group was performed in triplicate. Data are shown as the mean value  SD. Statistics are shown as com-
parisons between the treatment and control. **P  0.01. Insulin significantly increased HMEC-1 migration, and the effect of insulin on cell migration
correlated with the dose of insulin.
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precursor and the cleaved/mature forms of SREBP-1 showed an
increase in the mature form within 3 min. of insulin treatment
(Fig. 5A). To determine the involvement of SREBP-1 in insulin-
induced endothelial cell migration, we pre-treated these cells with
an SREBP inhibitor, 25-HC, and found that this inhibitor blocks cell
migration (Fig. 5B). In addition, the PI3K inhibitor LY294002 inhibits
SREBP-1 activation (Fig. 5C), suggesting that insulin-stimulated
SREBP-1 activation is mediated by PI3K-Akt, and that this activation
is important in insulin-induced cell migration.
To determine whether the PI3k-Akt-SREBP signalling pathway
activated by insulin in cultured endothelial cells is involved in
insulin-induced angiogenesis in vivo, we injected 25-HC to inhibit
SREBP prior to insulin treatment. This pre-treatment inhibited
insulin-induced angiogenesis, as shown by the decrease in the
area of CD31-positive cells (Fig. 6A–E), and a decreased number
of blood vessels staining with -SMA (Fig. 6F). These data, taken
together, show that the PI3k-Akt-SREBP signalling pathway is
involved in insulin-induced angiogenesis in vivo.
Insulin stimulates Rac1 membrane translocation
and this effect occurs downstream of the PI3K-
Akt-SREBP-1 pathway
SREBPs are the major regulators of HMG CoA reductase (HMGR)
[23, 24], which regulates the biosynthesis of farnesyl pyrophosphate
Fig. 3 Insulin stimulates microvascular endothelial cell migration in an insulin receptor-dependent and a VEGF-independent manner. Endothelial cells
were plated for the cloning ring migration assay, as described in Fig 2. (A) Cells were pre-treated with 1.5 g of the neutralising insulin receptor Ab
29B4 for 1 hr, and then treated with 10	7 M or 10	6 M insulin for 24 hrs. The neutralising insulin receptor Ab completely inhibited 10	7 M insulin-
induced cell migration and only partially inhibited 10	6 M insulin-induced cell migration, showing that the effect of 10	7 M insulin on endothelial cell
migration is mediated primarily through the insulin receptor. (B) Cells were pre-treated with either 50 nM IGF-1 receptor inhibitor picropodophyllin or
a combination of 1.5 g of the insulin receptor Ab 29B4 and picropodophyllin for 1 hr, then treated with 10	7 M or 10	6 M insulin or left untreated for
24 hrs. The effects of the higher insulin concentration are mediated by both the insulin receptor and the IGF-1 receptor, whereas lower insulin concen-
trations are mainly mediated by the insulin receptor alone. (C) Cells were treated with 10	7 M insulin for the indicated time-points, the cell culture
medium was then collected and VEGF levels were detected by Western blot. Insulin stimulates endothelial cell VEGF secretion. (D) Cells were either left
untreated or pre-treated with 8 nM VEGFR inhibitor SU1498 for 1 hr, followed by treatment with 10	7 M insulin or 20 ng/ml VEGF; migration distance
was measured at 24 and 48 hrs after treatment. Insulin-induced migration was not prevented with the VEGFR inhibitor, whereas VEGF-induced migra-
tion was prevented with this inhibitor. Each treatment group was performed in triplicate. Data are shown as the mean value  SD. Statistics are shown
as comparisons between the treatment and control, unless otherwise indicated. ***P  0.001.
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(FPP) and geranylgeranyl pyrophosphate (GGPP), two compo-
nents of isoprenoides that mediate the function of the RhoA 
family of GTPases [25–27]. As a consequence, we investigated
whether RhoA, a member of the RhoA family of GTPases, is acti-
vated by insulin. No significant difference in translocation of RhoA
to the plasma membrane (reflecting activation) was found after
insulin treatment (data not shown). However, Rac1, another mem-
ber of the RhoA family of GTPases, translocated from the cytosol
to the plasma membrane 3 min. after insulin treatment (Fig. 7A
and B). We also observed plasma membrane ruffling at the lead-
ing edge of migrating endothelial cells, with Rac-1 present in the
membrane of ruffles (Fig. 7C). To examine whether the transloca-
tion of Rac1 is associated with its activation, we performed a Rac
pull-down assay, which specifically pulls down and quantifies the
active form of Rac, and found elevated levels of active Rac1 after
insulin treatment (Fig. 7D).
To determine whether the Rac1 activation is essential in
insulin-induced endothelial cell migration, the cells were trans-
fected with plasmids containing mutant forms of Rac1, the consti-
tutively active form of Rac1 (V12, Rac1-CA), dominant-negative
mutant Rac1 (N17, Rac1-DN) or wild type Rac1 (Rac1-WT).
Twenty-four hours after transfection, the cells were seeded 
for cloning ring migration assays and plated on Matrigel for tube
formation assays. Cell migration distances were measured in non-
transfected and transfected cells at 24 and 48 hrs after insulin
treatment. Insulin-induced migration was observed in non-trans-
fected cells as well as in cells transfected with Rac1-CA or Rac1-
WT but was prevented in cells transfected with Rac1-DN (Fig. 8A).
Fig. 4 PI3K-Akt mediates insulin-induced microvascular endothelial cell
migration and tube formation: (A) Endothelial cells were treated with
10	7 M insulin for the indicated time-points, followed by Western blot
analysis using an antibody directed against Akt phosphorylated at Ser
473. The blot was re-probed with an anti-Akt Ab to ensure equal loading.
Insulin increased Akt phosphorylation over time, with peak phosphoryla-
tion seen at 3 and 15 min. (B) Cells were either left untreated or treated
with 10	8 M to10	5 M insulin for 3 min., and then analysed as in (A).
Insulin stimulated phosphorylation of Akt in a dose-dependent manner,
with 10	6 M and 10	5 M insulin inducing maximum phosphorylation. (C)
Cells were incubated with 25 M of the PI3K inhibitor LY294002 for 1 hr,
followed by treatment with 10	7 M insulin for the indicated time-points,
and Akt phosphorylation was detected by Western blot analysis, as men-
tioned above. Insulin-induced Akt phosphorylation was abrogated by pre-
treatment with a PI3K inhibitor. (D) Cells were incubated with 25 M of
the PI3K inhibitor LY294002 for 1 hr, followed by treatment with 10	7 M
insulin. The migration distances were measured at 24 and 48 hrs after
treatment. Insulin-induced endothelial cell migration was abrogated by
pre-treatment with a PI3K inhibitor. The results are representative of at
least three independent experiments. **P 0.01 versus control; ***P
0.001 versus control. (E) Cells were either left untreated as a control or
treated with 25 M of LY294002 for 1 hr, then treated with or without
10	7 M insulin, and the tube formation assay was performed. Each treat-
ment group was performed in triplicate. Insulin-induced tube formation
was prevented by pre-treatment with the PI3K inhibitor.
J. Cell. Mol. Med. Vol 13, No 11-12, 2009
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Similarly, insulin-induced tube formation was observed in non-
transfected cells (Fig. 8B and C) and in cells transfected with
Rac1-CA (Fig. 8D and E) or Rac1-WT (Fig. 8H and I) but not in
cells transfected with Rac1-DN (Fig. 8F and G). This suggests that
Rac1 is required for insulin-induced migration and tube formation.
To determine the involvement of the PI3K-Akt-SREBP pathway in
insulin-induced Rac activation, we pre-treated the cells with the
PI3K inhibitor LY294002 or the SREBP inhibitor 25-HC and found
that inhibition of these signalling molecules prevented insulin-
induced Rac1 activation (Fig. 8J and K), implicating the PI3K-Akt-
SREBP-1 pathway in insulin-induced Rac1 activation.
Discussion
The findings that insulin has a vascular protective effect on
endothelial cells and that it stimulates healing suggest that this
protein may stimulate angiogenesis, which in turn is instrumental
in accelerating wound healing. We show that: (1) Subcutaneous
injection of insulin stimulates the development of blood vessels
that are longer and have more branches than the vessels in vehi-
cle-treated animals and are associated with -SMA-expressing
cells. (2) Insulin stimulates microvascular endothelial cell migra-
tion, but not proliferation, in a dose- and time-dependent manner.
(3) Insulin stimulates endothelial tube formation in culture. (4)
The activities of insulin are dependent on the insulin receptor itself
and are independent of VEGF/VEGFR. (5) The PI3K-Akt-SREBP-1-
Rac1 signalling pathway is involved in insulin-induced endothelial
cell migration and tube formation in vitro and angiogenesis in vivo.
These results show for the first time the pro-angiogenic effects of
insulin and elucidate the signalling pathways stimulated by this
protein that result in angiogenesis.
The increase in microvessel branching stimulated by insulin 
in vivo is intriguing because it suggests stimulation of endothelial
cell proliferation. However, we were unable to detect insulin-
induced endothelial cell proliferation in the cultured endothelial
cells. This indicates that in vivo insulin cooperates with other fac-
tors that stimulate endothelial cell proliferation such as VEGF. One
possible explanation for this cooperation is that insulin stimulation
of glucose transport provides the energy that the cell needs to
then respond to proliferation stimuli. Our observation that more 
-SMA-expressing cells are associated with the microvessels in vivo
indicates that insulin also promotes blood vessel maturation. This
might be another process in which insulin could cooperate with
VEGF because it has been shown that VEGF-induced angiogenesis
results in leaky vessels [28, 29]. Indeed, following new microves-
sel development, the nascent vessels must undergo a maturation
process, both within the vascular network and within the vessel
wall, in order to function properly. Maturation of the vascular net-
work involves vascular branching, expansion and pruning [31],
whereas maturation of the vascular wall involves the recruitment
of mural cells, such as pericytes and smooth muscle cells that
express -SMA [32]. These cells are important support structures
Fig. 5 SREBP-1 is involved in insulin-induced endothelial cell migration
and activation by insulin, which requires the PI3K-Akt: (A, B) Endothelial
cells were treated with 10	7 M insulin for the indicated time-points. The
levels of the SREBP-1 precursor (‘P’) and mature/active (‘M’) forms were
analysed by Western blot. Blots were re-probed with GAPDH as a loading
control. (A) Insulin increased the levels of the mature form of SREBP-1,
with the active form peaking 15 min. after treatment. The levels of the
mature form of SREBP-1 were quantified by determining the ratio of the
integrated density of the mature form of SREBP-1 to GAPDH loading con-
trol, and further normalised to the control using ImageJ software. Data
are shown as the mean value  SD. Statistics are shown as comparisons
between the treatment and control. *P  0.05, **P  0.01. (B) Cell
migration was measured using the cloning ring assay. For 25-HC 
insulin-treated cells, cells were pre-treated with 10 g/ml 25-HC for 
24 hrs, followed by 10	7 M insulin treatment for 24 hrs. 25-HC significantly
inhibited insulin-induced endothelial cell migration. Each treatment group
was performed in triplicate. Data are shown as the mean value  SD.
Statistics are shown as comparisons between the treatment and control.
*P  0.05, **P  0.01. (C) Cells were pre-treated with 25 M of
LY294002 for 1 hr, followed by treatment with 10	7 M insulin for the indi-
cated time-points. SREBP-1 levels were detected by Western blotting.
Insulin-induced activation of SREBP-1 was inhibited by LY294002, as
shown by the decreased levels of mature SREBP-1.
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for the blood vessels [33–35]. Increases in both microvessel
branching and association with -SMA-expressing cells are
important for the transport of nutrients and proper O2/CO2
exchanges in the tissue and may contribute to the development of
a more regenerative tissue. Considering the importance of matu-
ration on the function of new blood vessel, the potential effects of
insulin on promoting the formation of more mature, functional
vessels puts insulin in the category of a valuable pro-angiogenic
molecule. Interestingly, despite our characterisation of insulin as a
pro-angiogenic factor, the insulin injection sites of diabetic
patients do not appear to exhibit pronounced angiogenesis. These
seemingly contradictory findings may result from a variety of fac-
tors, including the altered responsiveness of many diabetic
patients to insulin due to their reduced insulin sensitivity, dysfunc-
tional insulin-induced signalling pathways or reduced effective-
ness of insulin due to its non-enzymatic glycation or proteolysis
following injection. In addition, frequent sites for insulin injection
include the abdomen or buttocks, tissues with large amounts of
fat and relatively few blood vessels; the low numbers of pre-exist-
ing endothelial cells in these tissues might result in their lack of
obvious angiogenesis compared with the dermis in our animal
models. Furthermore, the insulin injection sites have not been fully
characterised; local insulin injection frequently results in a prob-
lem usually described as ‘hard lumps or extra fat deposits’, which
could contain granulation tissue and associated blood vessels that
could only be detected through a more thorough analysis; indeed,
our own analysis of blood vessels in insulin-treated mouse skin
involved tissue removal and specific staining for endothelial cells.
The activation of Rac1 downstream of a signalling pathway
involving PI3K, Akt and SREBP-1 is essential for insulin-induced
angiogenesis. SREBPs are potent regulators of lipogenic
enzymes and regulate the biosynthesis of cholesterol and fatty
acids [36–38], important components of the plasma membrane.
Increasing evidence suggests that SREBPs are the primary regu-
lators of HMGR [39, 24]. This enzyme regulates the biosynthesis
of FPP and GGPP [40], two components of isoprenoids.
Fig. 6 Inhibition of SREBP prevented insulin-induced angiogenesis in
mice skin: (A–E) Mice (n 
 4) were injected with insulin (0.03 U/20 l
saline), saline (20 l), 25-HC (20 l) or 25-HC (10 l)  insulin (0.03
U/10 l saline) at symmetric sites on the mouse dorsum every 24 hrs for
5 days, and skin samples were collected on day 6. Tissue slides were
stained with anti-CD31 antibody, as mentioned above. (A) 25-HC treat-
ment decreased the CD31-positive cell area and inhibited insulin-induced
blood vessel formation. Data are shown as the mean value  SD.
Statistics indicate differences between the treatment and control. ***P
0.001 versus control. (B–E) Representative immunofluorescence images
of CD31 staining. All pictures were taken at 40 and enlarged to the
same scale. (F) 25-HC treatment decreased the number of -SMA-posi-
tive blood vessels. -SMA-positive blood vessel number was calculated
as described in Fig. 1. Data are shown as the mean value  SD. Statistics
indicate differences between the treatment and control. *P 0.05 versus
control.
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Isoprenoids mediate the function of the RhoA family of GTPases
to which Rac1 belongs. These GTPases are geranylgeranylated
proteins, and inhibition of HMGR blocks the translocation or
redistribution of Rho family of proteins from the cytoplasm to the
membrane [41]. Also, Rac1 is known to regulate actin assembly
[42] and stimulate formation of lamellipodia [43], thereby pro-
moting cell movement in response to external signals from
cytokines, growth factors and/or the ECM. Therefore, inhibition of
SREBP-1 or the upstream signalling molecules PI3K/Akt prevents
insulin-induced Rac1 translocation and activation, thus inhibiting
cell migration.
Although insulin activates both its own receptor and/or IGF-1
receptor, our work shows that at lower doses insulin activates
only its own receptor to stimulate endothelial cell migration in
culture and angiogenesis in vivo. At higher concentrations,
insulin has additional growth factor-like activities through the
IGF receptor, which is known to be a potent regulator of cell
proliferation [44], differentiation [45] and survival [46].
Therefore, it is possible to take advantage of these differences
to treat various types of wounds. This may be particularly use-
ful in the treatment of chronic or impaired wounds in which tis-
sue insulin or its receptor might be deficient or dysfunctional.
However, it is important to realise that dysregulated IGF sig-
nalling is associated with many human cancers [47–51], sug-
gesting that insulin is a safer therapeutic option for the stimulation
of wound healing when compared with IGF-1 or other growth
factors. Indeed, insulin has a proven safety record, as it has
been used in human beings for a century, without serious side
effects.
In conclusion, because of the pro-angiogenic effects of insulin
and its safety for human applications, insulin may prove to be a
good therapy for the treatment of impaired wounds deficient in
revascularisation and other conditions in which re-vascularisation
is needed. However, problems could occur with insulin treatment
of impaired wounds in diabetic patients, which are generally asso-
ciated with peripheral vascular disease, endothelial dysfunction and
localised abnormalities in cellular and cytokine activity [52]. Insulin
dysfunction could occur through the non-enzymatic glycation of
this protein because of either the excessive levels of glucose in the
injured tissue or the deficiencies in the signalling downstream from
the insulin receptor. Furthermore, in other types of chronic
wounds, proper debridement might be a key to the success of
insulin therapy. As a consequence, more studies are needed to
examine the effects of insulin on angiogenesis in chronic wounds,
in particular in wounds of diabetic patients, as well as to determine
the most effective means of insulin delivery, including considera-
tions of the specific conditions found in the wound environment.
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Fig. 7 Insulin stimulates Rac1 translocation to the plasma membrane:
(A–C) Representative immunofluorescence images of Rac1 staining.
Cells were stained with the TRITC-anti-Rac1 Ab. Insulin induced Rac1
translocation to the plasma membrane. (C) The arrowhead indicates
membrane ruffling at the leading edge of a migrating cell. (D) Rac1 pull-
down assay. Endothelial cells were treated with insulin for 3 min., and the
Rac1 pull-down assay was then performed to quantify Rac activation. Cell
lysates were washed and mixed with PAK PBD agarose beads, and the
proteins pulled down were analysed by SDS-PAGE and immunoblotting
with an anti-Rac1 antibody. Insulin induced Rac1 activation.
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Fig. 8 Insulin-induced translocation of Rac1 occurs downstream of PI3K-Akt- SREBP-1. (A–I) Cells were transfected with plasmids expressing the con-
stitutively active form of Rac1 (V12, Rac1-CA), the dominant-negative mutant of Rac1 (N17, Rac1-DN) and the wild-type Rac1 (Rac1-WT) using
Lipofectin. Forty-eight hours after transfection, the cells were seeded for the cloning ring migration assay and tube formation assay. Cell migration was
monitored at 24 and 48 hrs after insulin treatment. Tube formation was observed after treatment for 20 hrs with insulin. (A) Insulin-induced endothe-
lial cell migration was eliminated by Rac1-DN, whereas Rac1-CA increased cell migration even without insulin treatment. Each treatment group was per-
formed in triplicate. Data are shown as the mean value  SD. Statistics are shown as comparisons between the treatment and control. *P  0.05, 
**P 0.01, ***P 0.001. (B–I) Insulin-induced endothelial cell tube formation was abolished by Rac1-DN. (J) Cells were pre-treated either with 25 M
PI3K inhibitor LY294002 for 1 hr or with 10 g/ml SREBP inhibitor 25-HC for 24 hrs, followed by 10	7 M insulin treatment for 3 min. The Rac1 pull-
down assay was then performed, as mentioned in Fig. 7. Insulin induced Rac1 activation, and this activation was prevented by inhibition of either PI3K
or SREBP. (K) Rac1 expression was quantified by the ratio of band density of activated Rac1/GAPDH using ImageJ software. Statistics are shown as
comparisons between the treatment and control, unless otherwise indicated, using three different gels.
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